Access to medicines: cost as an influence on the views and behaviour of patients

被引:66
|
作者
Schafheutle, EI [1 ]
Hassell, K [1 ]
Noyce, PR [1 ]
Weiss, MC [1 ]
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
关键词
cost sharing; health services accessibility; medication prescription fees; patient behaviour; prescription charges;
D O I
10.1046/j.1365-2524.2002.00356.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The present paper explores how charges for medicines incurred by patients influence their decisions for managing acute or chronic conditions, and whether prescription cost and affordability issues are discussed in the general practitioner (GP)-patient encounter. People suffering from dyspepsia, hay fever or hypertension, or those taking hormone replacement therapy, were recruited through three community pharmacies in the Northwest of England. Six focus groups were conducted with a total of 31 participants, the majority of whom were non-exempt from prescription charges. The management behaviour of those participants who had to pay for their prescriptions, particularly those from less-affluent or deprived backgrounds, was influenced by cost. However, cost was not the overriding influence, with other factors, such as symptom or disease severity, effectiveness, or necessity of treatment, playing a more important part in participants' management decisions. Cost as an issue was reflected in the various strategies used by participants to reduce medication cost, such as not having some prescribed items dispensed, taking a smaller dose or buying a cheaper over-the-counter product. Despite the use of numerous strategies, participants did not talk to their GPs about issues of cost and affordability. Participants felt that paying for prescriptions was their problem. There was a belief that discussing cost issues could jeopardise the doctor-patient relationship. Although not the dominant factor, medication cost nevertheless influenced participants when deciding how to manage their condition. Awareness of the existence of prepayment certificates, which can be bought by patients who require regular medication, was low, and this should be addressed through improved information/dissemination. Despite the high level of prescription items exempt, the current level of the prescription charge is still a barrier to obtaining prescription medicines under the National Health Service to those on lower incomes.
引用
收藏
页码:187 / 195
页数:9
相关论文
共 50 条
  • [1] General practitioners' views on the influence of cost on the prescribing of asthma preventer medicines: a qualitative study
    Tudball, Jacqueline
    Reddel, Helen K.
    Laba, Tracey-Lea
    Jan, Stephen
    Flynn, Anthony
    Goldman, Michele
    Lembke, Kirsty
    Roughead, Elizabeth
    Marks, Guy B.
    Zwar, Nick
    AUSTRALIAN HEALTH REVIEW, 2019, 43 (03) : 246 - 253
  • [2] COST AND PATIENTS ACCESS ANALYSIS TO REIMBURSED MEDICINES FOR MULTIPLE SCLEROSIS IN BULGARIA
    Seitaridou, Y.
    Kamusheva, M.
    Panayotov, P.
    Dimitrova, M.
    Petrova, G.
    VALUE IN HEALTH, 2020, 23 : S638 - S638
  • [3] THE BASIC HAMPER OF MEDICINES AS STRATEGY TO IMPROVE THE ACCESS AND COST OF MEDICINES IN PANAMA
    Conte, E.
    Gomez, B.
    Barahona, D.
    VALUE IN HEALTH, 2015, 18 (07) : A849 - A850
  • [4] The cost of prescription medicines to patients
    Noyce, PR
    Huttin, C
    Atella, V
    Brenner, G
    Haaijer-Ruskamp, FM
    Hedvall, MB
    Mechtler, R
    HEALTH POLICY, 2000, 52 (02) : 129 - 145
  • [5] RATIONING THE ACCESS TO HIGH COST MEDICINES IN DEVELOPING COUNTRIES
    Diniz, Debora
    DEVELOPING WORLD BIOETHICS, 2009, 9 (02) : II - III
  • [6] The great medicines scandal - Access is not just about cost
    Waning, BJ
    BRITISH MEDICAL JOURNAL, 2006, 333 (7557): : 44 - 44
  • [7] Barriers to access and use of high cost medicines: A review
    Wahlster, Philip
    Scahill, Shane
    Lu, Christine Y.
    Babar, Zaheer-Ud-Din
    HEALTH POLICY AND TECHNOLOGY, 2015, 4 (03) : 191 - 214
  • [8] ACCESS OF BULGARIAN PATIENTS TO BIOSIMILAR MEDICINES
    Tamer, J.
    Grozev, J.
    Kamusheva, M.
    Petrova, G.
    VALUE IN HEALTH, 2019, 22 : S787 - S787
  • [9] Patient access schemes for high-cost cancer medicines
    Williamson, Steve
    LANCET ONCOLOGY, 2010, 11 (02): : 111 - 112
  • [10] Time and cost involved in measuring access to medicines: the case of Albania
    E. Petro
    I. R. Joosse
    A. C. M. Siebers
    T. Martopullo
    R. P. M. Hart
    A. K. Mantel-Teeuwisse
    H. A. van den Ham
    F. Suleman
    BMC Research Notes, 18 (1)